# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
B of A Securities analyst Alexandria Hammond assumes 89bio (NASDAQ:ETNB) with a Buy rating and announces Price Target of $30.
BiBo will construct a production facility specifically designed to supply the Company with pegozafermin for commercialization, ...
Cantor Fitzgerald analyst Kristen Kluska reiterates 89bio (NASDAQ:ETNB) with a Overweight and maintains $29 price target.
HC Wainwright & Co. analyst Ed Arce maintains 89bio (NASDAQ:ETNB) with a Buy and maintains $31 price target.
–PRIME status is supported by positive data from the Phase 2b ENLIVEN trial of pegozafermin– –Phase 3 ENLIGHTEN-Fibrosis trial ...
HC Wainwright & Co. analyst Ed Arce maintains 89bio (NASDAQ:ETNB) with a Buy and maintains $31 price target.
Evercore ISI Group analyst Liisa Bayko maintains 89bio (NASDAQ:ETNB) with a Outperform and raises the price target from $29 ...
Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades.